BLS Pharmaceuticals has entered a non-binding heads of agreement with Trexapharm to explore the Australian commercialisation of TREXAVIVE, a proprietary, patented neurotherapy being developed for treatment-resistant depression. …
Latest Video
New Stories
-
Major brands and biosimilars feature prominently on November PBAC agenda
July 23, 2026 - - Latest News -
Bellberry and ASCEPT release checklist for 'new approach methodologies' trials
July 23, 2026 - - Latest News -
Faster processes could push Pharmac's options for investment backlog to 400 within two years
July 23, 2026 - -
How national HPV vaccination programs are changing the story of cervical cancer
July 23, 2026 - -
BLS and Trexapharm move to bring TREXAVIVE to Australian patients
July 22, 2026 - - BioPharma -
Radiopharm Theranostics reports positive results in tumour trials
July 22, 2026 - - Australian Biotech -
Proteomics International and Healius team up to take Promarker tests national
July 22, 2026 - - Australian Biotech